EGFR and non-small cell lung carcinoma: Numerous clinical trials have demonstrated the clinical benefit of immune checkpoint inhibitors (ICIs) in the management of NSCLC; however, ICI monotherapy exhibits limited benefit in patients harboring EGFR mutations.